JAZZ - Jazz Pharmaceuticals Public Limited Company

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
149.80
-0.39 (-0.26%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close150.19
Open152.16
Bid95.82 x 100
Ask177.77 x 100
Day's Range149.31 - 152.93
52 Week Range117.16 - 163.75
Volume630,005
Avg. Volume489,812
Market Cap8.981B
Beta1.22
PE Ratio (TTM)24.67
EPS (TTM)6.07
Earnings DateFeb 26, 2018 - Mar 2, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est179.48
Trade prices are not sourced from all markets
  • Concert Pharmaceuticals Plunges on Patent Petition Setback
    Zacks2 days ago

    Concert Pharmaceuticals Plunges on Patent Petition Setback

    Shares of Concert Pharmaceuticals (CNCE) nosedive after the Patent Trial and Appeal Board decided not to grant a Post Grant Review petition in patent '335 dispute with Incyte.

  • See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC.
    Markit5 days ago

    See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC.

    Jazz Pharmaceuticals PLC NASDAQ/NGS:JAZZ

  • Market Realist12 days ago

    How Jazz’s Erwinaze, Defitelio, and Prialt Performed in 3Q17

    In 3Q17, Jazz Pharmaceuticals’ (JAZZ) Erwinaze generated revenue of $49 million, which reflected a rise of ~14% on a year-over-year (or YoY) basis.

  • Market Realist13 days ago

    How Is Jazz Pharmaceuticals’ Xyrem Positioned after 3Q17?

    In 3Q17, Jazz Pharmaceuticals’ (JAZZ) Xyrem generated revenue of $303.9 million, which reflected a rise of ~6% on a YoY (year-over-year) basis.

  • Market Realist13 days ago

    How Did Jazz Pharmaceuticals Perform in 3Q17?

    In 3Q17, Jazz Pharmaceuticals generated revenue of $411.9 million, which reflected a ~10% rise on a year-over-year basis and a 4% rise on a quarter-over-quarter basis.

  • Market Realist13 days ago

    How Analysts Rated Jazz Pharmaceuticals in December

    In December 2017, Jazz Pharmaceuticals (JAZZ) submitted a New Drug Application (or NDA) to the FDA for the approval of JZP-110.

  • PR Newswire15 days ago

    Jazz Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference on January 8

    A live audio webcast of the presentation may be accessed from the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com.  Please connect to the website prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast. An archive of the webcast will be available for at least one week following the presentation on the Investors section of the company's website at www.jazzpharmaceuticals.com. Jazz Pharmaceuticals plc (JAZZ) is an international biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing meaningful products that address unmet medical needs.  The company has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.  In these areas, Jazz Pharmaceuticals markets Xyrem® (sodium oxybate) oral solution, Erwinaze® (asparaginase Erwinia chrysanthemi), Defitelio® (defibrotide sodium) and Vyxeos™ (daunorubicin and cytarabine) liposome for injection in the U.S. and markets Erwinase® and Defitelio® (defibrotide) in countries outside the U.S.  For more information, please visit www.jazzpharmaceuticals.com.

  • See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC.
    Markit15 days ago

    See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC.

    Jazz Pharmaceuticals PLC NASDAQ/NGS:JAZZ

  • Capital Cube22 days ago

    ETFs with exposure to Jazz Pharmaceuticals Plc : December 26, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Jazz Pharmaceuticals Plc Here are 5 ETFs with the largest exposure to JAZZ-US. Comparing the performance and risk of Jazz Pharmaceuticals Plc with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Jazz Pharmaceuticals Plc :JAZZ-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017
    Capital Cube23 days ago

    Jazz Pharmaceuticals Plc :JAZZ-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017

    Categories: Yahoo FinanceGet free summary analysis Jazz Pharmaceuticals Plc reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Jazz Pharmaceuticals Plc – Valeant Pharmaceuticals International Inc, Endo International Plc, Paratek Pharmaceuticals Inc, Novartis AG Sponsored ADR, Teva Pharmaceutical Industries Limited Sponsored ADR and AmerisourceBergen Corporation (VRX-US, ... Read more (Read more...)

  • Jazz Submits NDA to FDA for JZP-110 to Cure Sleep Disorder
    Zacks26 days ago

    Jazz Submits NDA to FDA for JZP-110 to Cure Sleep Disorder

    Jazz submits a new drug application to the FDA for JZP-110 (solriamfetol) for treatment of excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea.

  • PR Newswire27 days ago

    Jazz Pharmaceuticals Submits New Drug Application for Solriamfetol (JZP-110) for Excessive Sleepiness Associated with Narcolepsy and Obstructive Sleep Apnea

    DUBLIN, Dec. 21, 2017 /PRNewswire/ -- Jazz Pharmaceuticals plc (JAZZ) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration on December 20, 2017 seeking marketing approval for solriamfetol (JZP-110), an investigational medicine for the treatment of excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea (OSA). The solriamfetol Phase 3 clinical program includes one study evaluating excessive sleepiness in adult patients with narcolepsy (TONES 2), two studies evaluating excessive sleepiness in adult patients with OSA (TONES 3 and TONES 4), and an open-label, long-term safety and maintenance of efficacy study (TONES 5) in the treatment of excessive sleepiness in patients with narcolepsy or OSA.

  • The Loopholes Drug Companies Use to Keep Prices High
    Bloomberg28 days ago

    The Loopholes Drug Companies Use to Keep Prices High

    Drugmakers are using a variety of strategies to extend the exclusivity period of their wares, keeping less expensive alternatives away from patients.

  • Can Jazz Pharmaceuticals Public Limited Company’s (NASDAQ:JAZZ) ROE Continue To Surpass The Industry Average?
    Simply Wall St.28 days ago

    Can Jazz Pharmaceuticals Public Limited Company’s (NASDAQ:JAZZ) ROE Continue To Surpass The Industry Average?

    Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ) delivered an ROE of 17.79% over the past 12 months, which is an impressive feat relative to its industry average of 11.92% during theRead More...

  • Reuterslast month

    Pennsylvania man admits to trading on tips about drug company

    Daniel Perez, who authorities said lived next door to a former Celator accountant in Yardley, Pennsylvania, entered his plea to one count of securities fraud in federal court in Trenton, New Jersey, prosecutors said. Prosecutors at that time announced that three other people, including Evan Kita, the former employee at the New Jersey drug company, had pleaded guilty to participating in the insider trading scheme. Prosecutors said Kita told Perez and another friend, Richard Yu, in 2016 that clinical trials for his company's leukemia drug had produced positive results, allowing both men to place trades before Celator announced the news.

  • Reuterslast month

    Pennsylvania man admits to trading on tips about drug company

    A Pennsylvania man pleaded guilty on Friday to charges that he traded on confidential, inside information that a former Celator Pharmaceuticals Inc employee supplied him, including that the company now owned by Jazz Pharmaceuticals Plc was planning to be acquired. Daniel Perez, who authorities said lived next door to a former Celator accountant in Yardley, Pennsylvania, entered his plea to one count of securities fraud in federal court in Trenton, New Jersey, prosecutors said. Prosecutors at that time announced that three other people, including Evan Kita, the former employee at the New Jersey drug company, had pleaded guilty to participating in the insider trading scheme.

  • December Top Growth Stocks
    Simply Wall St.last month

    December Top Growth Stocks

    High-growth stocks that are financially stable are attractive for many reasons. They provide a strong upside to your portfolio, with less likelihood of downside risks compared to less financially robustRead More...

  • Capital Cubelast month

    Jazz Pharmaceuticals Plc – Value Analysis (NASDAQ:JAZZ) : December 13, 2017

    Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Jazz Pharmaceuticals Plc a score of 81. Our analysis is based on comparing Jazz Pharmaceuticals Plc with the following peers – Valeant Pharmaceuticals International Inc, Endo International Plc, Paratek Pharmaceuticals Inc, Novartis AG Sponsored ADR, Teva Pharmaceutical Industries Limited Sponsored ADR and AmerisourceBergen Corporation (VRX-US, ENDP-US, PRTK-US, ... Read more (Read more...)

  • Jazz Pharmaceuticals Plc breached its 50 day moving average in a Bullish Manner : JAZZ-US : December 12, 2017
    Capital Cubelast month

    Jazz Pharmaceuticals Plc breached its 50 day moving average in a Bullish Manner : JAZZ-US : December 12, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Jazz Pharmaceuticals Plc. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bearish ... Read more (Read more...)

  • See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC.
    Markitlast month

    See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC.

    Jazz Pharmaceuticals PLC NASDAQ/NGS:JAZZ

  • PR Newswirelast month

    Jazz Pharmaceuticals to Present at the BMO Capital Markets Healthcare Conference

    A live audio webcast of the presentation may be accessed from the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com.  Please connect to the website prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast. An archive of the webcast will be available for at least one week following the presentation on the Investors section of the company's website at www.jazzpharmaceuticals.com. Jazz Pharmaceuticals plc (JAZZ) is an international biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing meaningful products that address unmet medical needs.  The company has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.  In these areas, Jazz Pharmaceuticals markets Xyrem® (sodium oxybate) oral solution, Erwinaze® (asparaginase Erwinia chrysanthemi), Defitelio® (defibrotide sodium) and Vyxeos™ (daunorubicin and cytarabine) liposome for injection in the U.S. and markets Erwinase® and Defitelio® (defibrotide) in countries outside the U.S.  For more information, please visit www.jazzpharmaceuticals.com.

  • GlobeNewswirelast month

    Vital Therapies Appoints Russell J. Cox as Chief Executive Officer and Board Member Effective January 3, 2018

    SAN DIEGO, Dec. 04, 2017-- Vital Therapies, Inc., a biotherapeutic company developing ELAD ®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced the appointment ...

  • PR Newswirelast month

    Jazz Pharmaceuticals Announces Appointment Of Daniel Swisher As President And Chief Operating Officer

    DUBLIN, Dec. 4, 2017 /PRNewswire/ -- Jazz Pharmaceuticals plc (JAZZ) today announced the appointment of Daniel N. Swisher, Jr. as president and chief operating officer, effective January 3, 2018.  Mr. Swisher will report to Bruce Cozadd, chairman and chief executive officer.  Russell J. Cox, who has served as the company's executive vice president and chief operating officer since 2014, has resigned, effective January 3, 2018, to assume the role of Chief Executive Officer and member of the Board of Directors at a biotherapeutic company that is focused on helping patients with acute forms of liver failure.

  • Drug Charity May Shutter After U.S. Faults Pharma Influence
    Bloomberg2 months ago

    Drug Charity May Shutter After U.S. Faults Pharma Influence

    A medical charity that received hundreds of millions of dollars from pharmaceutical companies lost a crucial stamp of approval from the U.S. government, after allowing its donors improper influence over ...

  • See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC.

    Jazz Pharmaceuticals PLC NASDAQ/NGS:JAZZ